Wellington Management Group LLP Acquires 477,557 Shares of Novo Nordisk A/S (NYSE:NVO)

Wellington Management Group LLP lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 135.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 830,435 shares of the company's stock after acquiring an additional 477,557 shares during the quarter. Wellington Management Group LLP's holdings in Novo Nordisk A/S were worth $71,434,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after purchasing an additional 1,165,955 shares during the period. GQG Partners LLC lifted its position in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares during the period. Loomis Sayles & Co. L P lifted its position in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the period. Folketrygdfondet increased its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock valued at $765,917,000 after buying an additional 40,313 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Novo Nordisk A/S by 1.5% in the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock valued at $715,084,000 after buying an additional 123,681 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NVO. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Stock Up 2.8%

Shares of Novo Nordisk A/S stock traded up $1.94 on Friday, hitting $71.40. 11,185,051 shares of the company traded hands, compared to its average volume of 6,787,412. The company has a 50-day moving average price of $65.63 and a 200 day moving average price of $82.01. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The company has a market cap of $320.41 billion, a PE ratio of 21.70, a PEG ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion for the quarter. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.